MarketFriction

Par Drugs & Chemicals Ltd

NSE PAR · Pharmaceuticals
₹123.95 -2.12%
NSE close2026-10-01
52 week range78.05 - 180.00
Market cap₹154 Cr.
P/E10.6
IPO 2019 · +143% since ESM Price band 5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales25.8924.0022.8222.6134.6621.3822.3326.0528.6629.3419.6131.28
Expenses18.5318.7716.7218.3723.2519.9519.9022.4922.6023.2918.1724.91
Operating Profit7.365.236.104.2411.411.432.433.566.066.051.446.37
OPM %28.43%21.79%26.73%18.75%32.92%6.69%10.88%13.67%21.14%20.62%7.34%20.36%
Other Income0.050.23-0.050.071.020.270.791.840.481.330.360.94
Interest0.030.020.050.020.030.010.020.020.050.010.040.02
Depreciation0.850.870.890.900.910.910.920.900.940.930.930.96
Profit before tax6.534.575.113.3911.490.782.284.485.556.440.836.33
Tax %25.27%25.16%27.20%25.07%25.15%24.36%27.63%25.67%25.59%25.47%-3.61%25.59%
Net Profit4.893.423.722.538.600.581.653.334.134.800.854.71
EPS in Rs3.972.783.022.066.990.471.342.713.363.900.693.83
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales334942465661759696101104109
Expenses264034384645597873818789
Operating Profit7888916161823201720
OPM %22%17%19%18%17%26%22%19%24%19%17%18%
Other Income000002000243
Interest422211000000
Depreciation333333333444
Profit before tax1333615131520181719
Tax %58%42%42%24%21%21%27%25%26%26%24%
Net Profit022351291114131314
EPS in Rs0.783.432.782.793.879.447.499.2111.7810.8610.6511.78
Dividend Payout %0%0%0%0%32%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth12%11%3%4%
Compounded Profit Growth38%1%-2%2%
Stock Price CAGR%-10%-16%19%
Return on Equity15%14%13%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital33334661212121212
Reserves99111225344648597387100
Borrowings38363129126800000
Other Liabilities91012101113161918162017
Total Liabilities595856545160767989102119129
Fixed Assets454342393634303438413936
CWIP000001500001
Investments00000000002527
Other Assets131514151525424450605565
Total Assets595856545160767989102119129
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity97942812813201616
Cash from Investing Activity-0-0-2-1-0-10-3-7-6-25-2
Cash from Financing Activity-9-5-8-4-212-100000
Net Cash Flow-11-10-0714-5614-914
Free Cash Flow9674261246141514
CFO/OP127%91%116%59%34%90%98%66%97%108%106%125%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days838161756781759065526042
Inventory Days11115869838145506049455845
Days Payable1841831351079496112135735810469
Cash Conversion Cycle1057-5515530131440401519
Working Capital Days6166-46-261339246150403931
ROCE %10%9%12%11%12%16%25%22%23%25%18%15%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters74.21%74.21%74.21%74.21%73.37%73.37%73.37%73.37%73.37%73.41%73.41%73.41%
FIIs0.00%0.07%0.07%0.32%0.09%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DIIs0.00%0.00%0.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.09%
Public25.79%25.73%25.68%25.47%26.54%26.63%26.63%26.63%26.63%26.59%26.59%26.51%
No. of Shareholders5,9027,0207,4038,0228,75717,18915,47214,88714,28013,76113,22212,782

Fundamentals

Market Cap₹ 154 Cr.
Current Price₹ 125
Stock P/E10.6
Book Value₹ 91.0
ROCE14.6 %
ROE9.95 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)2%
Standalone figures.
Valuation
Market capRs 153 Cr
Enterprise valueRs 111 Cr
P/E (TTM)10.53x
Price to book1.36x
Price to sales1.40x
EV / EBITDA4.81x
EV / EBIT5.74x
EV / sales1.02x
Price to cash flow9.28x
Earnings yield9.50%
P/E, 3-year average11.16x
P/B, 3-year average1.67x
P/E, 5-year average14.01x
P/B, 5-year average2.14x
Profitability
Operating margin (excl. other income)16.53%
Operating margin (incl. other income)20.39%
EBITDA margin21.15%
Pre-tax margin17.59%
Net profit margin13.31%
Net margin, latest quarter15.06%
ROE12.43%
ROCE16.53%
ROA10.55%
ROE, 3-year average15.13%
ROCE, 3-year average20.35%
ROA, 3-year average12.62%
ROE, 5-year average15.82%
ROCE, 5-year average21.22%
ROA, 5-year average12.65%
ROIC (approx.)20.82%
Tax rate24.22%
Other income / net worth3.57%
Growth
Sales growth (latest year)2.65%
Profit growth (latest year)-1.87%
Sales CAGR, 3 years2.68%
Sales CAGR, 5 years11.28%
Profit CAGR, 3 years4.98%
Profit CAGR, 5 years2.46%
Sales growth QoQ59.51%
Profit growth QoQ454.12%
Sales growth YoY (latest quarter)20.08%
Profit growth YoY (latest quarter)41.44%
Per share
EPS (TTM)Rs 11.78
EPS (latest year)Rs 10.65
EPS (latest quarter)Rs 3.83
EPS, 3-year averageRs 11.10
EPS, 5-year averageRs 10.00
Book value per shareRs 91.01
Sales per shareRs 88.50
Cash flow per shareRs 13.35
Free cash flow per shareRs 11.38
Efficiency
Asset turnover0.80x
Fixed asset turnover2.84x
Inventory turnover12.70x
Inventory days29 days
Debtor days42 days
Debtors turnover8.62x
Creditor days69 days
Cash conversion cycle19 days
Working capital days31 days
Leverage
Cash and bankRs 42 Cr
Net debtRs -42 Cr
Net debt / EBITDA-1.82x
Interest coverage160.58x
Owners' fund to total sources86.67%
Cash flow
Cash from Operating Activity (latest year)Rs 16 Cr
Cash from Investing Activity (latest year)Rs -2 Cr
Net Cash Flow (latest year)Rs 14 Cr
Free cash flow (latest year)Rs 14 Cr
Cash from ops / profit, 5 years1.22x
Sales to cash flow6.31x
Statement figures
Net sales (TTM)Rs 109 Cr
Net sales (latest year)Rs 104 Cr
Sales (latest quarter)Rs 31 Cr
Operating profit excl. other income (latest year)Rs 17 Cr
Operating profit (latest quarter)Rs 6 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 23 Cr
PBDT (TTM)Rs 23 Cr
Profit before tax (TTM)Rs 19 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 14 Cr
Net profit (latest year)Rs 13 Cr
Net profit (latest quarter)Rs 5 Cr
Depreciation (TTM)Rs 4 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 68 Cr
Total expenditure (latest year)Rs 87 Cr
Total income (latest year)Rs 108 Cr
Share capitalRs 12 Cr
ReservesRs 100 Cr
Shareholders' fundsRs 112 Cr
Total assetsRs 129 Cr
Net blockRs 36 Cr
Capital work in progressRs 1 Cr
InvestmentsRs 27 Cr
ReceivablesRs 12 Cr
InventoryRs 5 Cr
Other liabilitiesRs 17 Cr
Shares outstanding (crore)1.23
Ownership
Promoter holding73.41% (+0.04 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 10.5 is at the 19th percentile of its own 7.5-year range (median 18.7, low 6.8, high 40.6).
P/B 1.36 is at the 19th percentile (median 2.47).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodPARNifty 50Difference
1 week-5.6%-2.8% -2.8 pts
1 month-11.8%-6.8% -5.1 pts
3 months+36.7%-7.6% +44.3 pts
6 months+57.7%+0.4% +57.3 pts
1 year+14.3%-9.9% +24.2 pts
2 years-49.1%-13.6% -35.5 pts
3 years-41.3%+14.2% -55.5 pts
5 years-43.9%+27.9% -71.8 pts

Red flags

F-score 5 of 8
lookRegulator order or action Regulator order or action 2026-06-10: Par Drugs And Chemicals Limited has informed the Exchange about Action(s) taken or orders passed
lookOn NSE surveillance On NSE surveillance: ESM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹31 Cr +20.1% vs Jun 2025. Net profit ₹5 Cr +41.4%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-12-23Extra Ordinary General Meeting
2024-09-13Annual General Meeting
2023-09-08Annual General Meeting
2022-09-01Annual General Meeting
2021-11-22 Interim Dividend - Rs 1.25 Per Share
DateTypeWhat it says
2026-09-27Shareholder meetingVoting results.
2026-09-26UpdatesProceeding of AGM dated 26.09.2026.
2026-09-26Shareholder meetingProceedings of Annual General Meeting held on September 26, 2026
2026-09-01UpdatesRegulation 36 (1)(b).
2026-08-22Shareholder meetingNotice of Annual General Meeting to be held on September 26, 2026
2026-08-22Board meeting outcomeOutcome of Board Meeting held on August 22, 2026.
2026-08-22AppointmentAppointment of M/s Maulin Shah & Associates, Cost Accountant as Cost Auditor of the Company w.e.f. April 01, 2026.
2026-08-22AppointmentAppointment of Ms SIDDHPURA & CO, Internal Auditor as Internal auditor of the company w.e.f. April 01, 2026.
2026-08-22UpdatesOutcome of Board Meeting dated 22.08.2026.
2026-08-08UpdatesOutcome of Board Meeting dated 08.08.2026.
2026-08-08Board meeting outcomeOutcome of Board Meeting held on August 08, 2026.
2026-08-08Board meeting outcomePar Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-06-10Regulatory actionAction(s) taken or orders passed
2026-05-21Regulatory actionAction(s) initiated or orders passed
2026-05-14Board meeting outcomeOutcome of Board Meeting held on May 14, 2026.
2026-05-14UpdatesOutcome of Board Meeting 14.05.2026.
2026-05-14UpdatesOutcome of the Board Meeting dated 14.05.2026.
2026-05-14Board meeting outcomeOutcome of Board Meeting held on May 14, 2026.
2026-05-14Board meeting outcomePar Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-08Disclosure under SEBI TakeovPar Drugs And Chemicals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indi...
2026-03-26Regulatory actionAction(s) taken or orders passed
2026-02-10UpdatesOutcome of Board Meeting dated 10.02.2026.
2026-02-10Board meeting outcomeBoard meeting held on February 10, 2026.
2026-02-10Board meeting outcomeOutcome of Board Meeting held on February 10, 2026.
2026-02-10Board meeting outcomePar Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03